001440552 000__ 03547cam\a2200553\a\4500
001440552 001__ 1440552
001440552 003__ OCoLC
001440552 005__ 20230309004611.0
001440552 006__ m\\\\\o\\d\\\\\\\\
001440552 007__ cr\un\nnnunnun
001440552 008__ 211027s2021\\\\sz\\\\\\o\\\\\001\0\eng\d
001440552 019__ $$a1280603257$$a1281134110$$a1287773506$$a1287871362$$a1292518825
001440552 020__ $$a9783030797904$$q(electronic bk.)
001440552 020__ $$a3030797902$$q(electronic bk.)
001440552 020__ $$z3030797899
001440552 020__ $$z9783030797898
001440552 0247_ $$a10.1007/978-3-030-79790-4$$2doi
001440552 035__ $$aSP(OCoLC)1280461997
001440552 040__ $$aYDX$$beng$$epn$$cYDX$$dGW5XE$$dEBLCP$$dDCT$$dOCLCF$$dDKU$$dOCLCO$$dOCLCQ$$dFAU$$dUKAHL$$dOCLCQ
001440552 049__ $$aISEA
001440552 050_4 $$aRM332
001440552 08204 $$a616.85/27061$$223
001440552 24500 $$aNew rapid-acting antidepressants /$$cKenji Hashimoto, Mario Manto, editors.
001440552 260__ $$aCham, Switzerland :$$bSpringer,$$c2021.
001440552 300__ $$a1 online resource
001440552 336__ $$atext$$btxt$$2rdacontent
001440552 337__ $$acomputer$$bc$$2rdamedia
001440552 338__ $$aonline resource$$bcr$$2rdacarrier
001440552 347__ $$atext file
001440552 347__ $$bPDF
001440552 4901_ $$aContemporary clinical neuroscience,$$x2627-5341
001440552 500__ $$aIncludes index.
001440552 5050_ $$a(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
001440552 506__ $$aAccess limited to authorized users.
001440552 520__ $$aThis book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.
001440552 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed October 27, 2021).
001440552 650_0 $$aAntidepressants.
001440552 655_7 $$aLlibres electrònics.$$2thub
001440552 655_0 $$aElectronic books.
001440552 7001_ $$aHashimoto, Kenji,$$cPh. D.,$$eeditor.
001440552 7001_ $$aManto, Mario,$$eeditor.
001440552 77608 $$iPrint version:$$tNew rapid-acting antidepressants.$$dCham, Switzerland : Springer, 2021$$z3030797899$$z9783030797898$$w(OCoLC)1253474515
001440552 830_0 $$aContemporary clinical neuroscience,$$x2627-5341
001440552 852__ $$bebk
001440552 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-79790-4$$zOnline Access$$91397441.1
001440552 909CO $$ooai:library.usi.edu:1440552$$pGLOBAL_SET
001440552 980__ $$aBIB
001440552 980__ $$aEBOOK
001440552 982__ $$aEbook
001440552 983__ $$aOnline
001440552 994__ $$a92$$bISE